Insider track record
OtherNot enough buy signals with a settled T+90 horizon to measure a track record yet.
Discover the full record of transactions filed by Ogden Christopher. Officer active across 1 company, notably CytomX Therapeutics, Inc.. Cumulatively, 14 disclosures have been published. Breakdown: 0 buy · 7 sells. Total volume traded: €126k. Activity tracked since 2 February 2023. The latest transaction was filed on 17 March 2026 (Cession). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Ogden Christopher
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
1,624 sharesCommon StockSEC:0001610717-26-000229:0
19,323 shares@ US$6.42385.7% of flowCommon StockSEC:0001610717-26-000122:0
90,000 shares0Common StockSEC:0001610717-26-000040:0
1,641 shares@ US$2.950323.1% of flowCommon StockSEC:0001610717-25-000236:0
8,551 shares@ US$0.59933.9% of flowCommon StockSEC:0001610717-25-000085:0
44,000 shares0Common StockSEC:0001610717-25-000017:0
6,875 shares0Common StockSEC:0001610717-24-000433:0
17,500 shares0Common StockSEC:0001610717-24-000339:0
2,971 shares@ US$2.085541.1% of flowCommon StockSEC:0001610717-24-000177:0
40,000 shares0Common StockSEC:0001610717-24-000034:0
1,990 shares@ US$1.380618.1% of flowCommon StockSEC:0001610717-23-000419:0
6,875 shares0Common StockSEC:0001610717-23-000412:0
516 shares@ US$1.97937.0% of flowCommon StockSEC:0001140361-23-012619:0
25,000 shares0Common StockSEC:0001567619-23-001927:0
About Ogden Christopher
Ogden Christopher is a declarant linked to CytomX Therapeutics, Inc., where he serves as Chief Financial Officer. He has 14 filings in total, and across the 14 sampled filings between 2023-02-06 and 2026-06-17, the recorded activity is a sale, with sum_buy_eur at 0 and sum_sell_eur at 125957.